148 related articles for article (PubMed ID: 38613358)
1. Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.
Choi E; Jeon KH; Lee H; Mun GI; Kim JA; Shin JH; Kwon Y; Na Y; Lee YS
Cancer Sci; 2024 Jun; 115(6):2036-2048. PubMed ID: 38613358
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
3. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
4. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
[TBL] [Abstract][Full Text] [Related]
6. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of cathepsin S expression by HSP90 and 5-HT
Gautam J; Bae YK; Kim JA
Breast Cancer Res Treat; 2017 Jan; 161(1):29-40. PubMed ID: 27796714
[TBL] [Abstract][Full Text] [Related]
8. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
9. BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer.
Sriramulu S; Thoidingjam S; Chen WM; Hassan O; Siddiqui F; Brown SL; Movsas B; Green MD; Davis AJ; Speers C; Walker E; Nyati S
J Exp Clin Cancer Res; 2024 Jun; 43(1):163. PubMed ID: 38863037
[TBL] [Abstract][Full Text] [Related]
10. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
11. Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation.
Kim S; Jin H; Seo HR; Lee HJ; Lee YS
Cell Death Differ; 2019 May; 26(5):812-825. PubMed ID: 30006610
[TBL] [Abstract][Full Text] [Related]
12. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
14. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
16. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
Li HC; Xia ZH; Chen YF; Yang F; Feng W; Cai H; Mei Y; Jiang YM; Xu K; Feng DX
Cell Physiol Biochem; 2017; 43(5):1829-1840. PubMed ID: 29050003
[TBL] [Abstract][Full Text] [Related]
17. Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Luo J; Dai X; Hu H; Chen J; Zhao L; Yang C; Sun J; Zhang L; Wang Q; Xu S; Xu Y; Liu N; Ying G; Wang P
J Cancer Res Clin Oncol; 2020 Mar; 146(3):721-737. PubMed ID: 31786739
[TBL] [Abstract][Full Text] [Related]
18. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Dinkelborg PH; Wang M; Gheorghiu L; Gurski JM; Hong TS; Benes CH; Juric D; Jimenez RB; Borgmann K; Willers H
Breast Cancer Res Treat; 2019 Apr; 174(3):605-613. PubMed ID: 30607635
[TBL] [Abstract][Full Text] [Related]
19. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
[TBL] [Abstract][Full Text] [Related]
20. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
